-
Tesaro Gets Approval For Zejula, Expect U.S. Launch Late April
Tuesday, March 28, 2017 - 10:26am | 363Read More...TESARO Inc (NASDAQ: TSRO) announced the FDA approval of Zejula (niraparib) in recurrent ovarian cancer maintenance with a broad label. The approval came in three months ahead of schedule and the launch is expected in late April, Baird’s Michael E. Ulz said in a report. While reiterating a...
-
Breaking Down The Crowded Novel Ovarian Cancer Treatment Space
Wednesday, December 21, 2016 - 10:19am | 621Read More...The incidence of ovarian cancer is supposed to be sporadic, with just about 3 percent of cancers among women said to originate from the ovaries. However, it is considered more lethal than any other cancer of female reproductive system. Clovis' Slice Of Luck So when the FDA granted accelerated...
-
Wedbush Previews Medivation's Q2 Earnings, Sees Takeout In Mid- To High-$60 Range
Tuesday, July 12, 2016 - 9:01am | 314Read More...Wedbush’s David M. Nierengarten believes that a likely takeout price for Medivation Inc (NASDAQ: MDVN) would be in the mid- to high-$60 per share range, including the probable realized value of any CVR for Talazoparib. Nierengarten reiterated an Outperform rating on the company, while raising...
-
Medivation Bidders Will Have To Price In Talazoparib; BMO Sees $68-$76 Takeout Price
Thursday, July 7, 2016 - 3:33pm | 462Read More...As multiple suitors line up to acquire Medivation Inc (NASDAQ: MDVN), BMO Capital said a winning bid will require an acceptable value for Talazoparib, likely a premium over the $410 million upfront payment to BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). The Talazoparib Issue Last year, Medivation...
-
Credit Suisse Says Medivation Market Value Is Approaching Its Target
Thursday, July 7, 2016 - 8:11am | 307Read More...Medivation Inc (NASDAQ: MDVN) has rejected a hostile takeover bid by Sanofi SA (ADR) (NYSE: SNY) offering $58 per share in cash with contingent value rights of $3 per share for Talazoparib. It is believed that a disagreement over the cancer treatment drug value is holding up the deal. According to...
-
Stifel Lays Out 3 Scenarios For Medivation Takeover
Monday, May 2, 2016 - 2:49pm | 318Read More...Stifel analyst Thomas Shrader laid out three scenarios for Medivation Inc (NASDAQ: MDVN) takeover after the biopharma company rejected Sanofi SA (ADR) (NYSE: SNY)'s $52.50 acquisition bid. Shrader raised his target price on the stock by $14 to $66, which is also his minimum takeover price for...
-
Here's What Medivation Said In Its Rejection Letter To Sanofi
Friday, April 29, 2016 - 2:38pm | 361Read More...Medivation Inc (NASDAQ: MDVN) disclosed on Friday a letter it has written to Sanofi SA (ADR) (NYSE: SNY) with regards to its acquisition offer to buy the company for $52.50 per share. Medivation started off by stating its Board of Directors unanimously rejected Sanofi's proposal to fully...
-
SunTrust: Medivation M&A Chatter Highlights Value, Company's 'Unique' Industry Position
Wednesday, April 13, 2016 - 1:44pm | 623Read More...The M&A rumors continue to swirl around biotech firm Medivation Inc (NASDAQ: MDVN), and a SunTrust analyst has commented that the latest take-over chatter highlights the value of the company. A Bloomberg report said Medivation has rejected a take-out offer from Sanofi SA (ADR) (NYSE: SNY),...
